New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Jürgen C BeckerRoland Houben

Abstract

Recent results from basic and translational research on tumor genesis and progression establish the basis for future therapeutic approaches. Targeted therapeutics are tailored toward the molecular abnormalities that cause tumor progression and could potentially provide an effective, non-toxic therapeutic approach in a broad range of cancers including melanoma. Cancer is as much a (cyto)genetic disease as it is an epigenetic disease. Indeed, the fate of the cell depends on a delicate balance between expression and repression of genes. The notion that drastic changes in DNA methylation and histone modifications are present in a variety of human tumors has prompted the development and characterization of epigenetic drugs. Inhibitors of histone deacetylases and methyltransferases as well as of the proteasome are covered in this review.

References

Jul 15, 1996·The Journal of Clinical Investigation·S StrömbladD A Cheresh
Mar 3, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y KanaiS Hirohashi
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Jun 5, 2001·Journal of Cellular Biochemistry. Supplement·H Leonhardt, M C Cardoso
Nov 2, 2001·Nature·T ReyaI L Weissman
Dec 19, 2001·The Journal of Pathology·Manel Esteller, James G Herman
Aug 3, 2002·Oncogene·Adam R Karpf, David A Jones
Jan 27, 2004·Journal of Cellular Biochemistry·Alan Eastman
Apr 13, 2004·Current Opinion in Oncology·Keith T Flaherty
Apr 28, 2004·Current Opinion in Genetics & Development·Muhammad Al-HajjMichael F Clarke
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Jul 29, 2004·Current Pharmaceutical Design·Richard Piekarz, Susan Bates
Aug 3, 2004·Nature Medicine·Bert Vogelstein, Kenneth W Kinzler
Sep 8, 2004·International Journal of Cancer. Journal International Du Cancer·Ana Villar-Garea, Manel Esteller
Nov 10, 2004·Seminars in Hematology·Michael R DeBaun
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfram E SamlowskiAdam R Karpf
May 11, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre J IssaHagop M Kantarjian
Jun 22, 2005·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Petra Boukamp

❮ Previous
Next ❯

Citations

Aug 10, 2007·Molekuliarnaia biologiia·Changjun MuGuo-Chang Zheng
Apr 30, 2009·Experimental Dermatology·Roland HoubenJürgen C Becker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology
Cora Mund, Frank Lyko
International Journal of Molecular Sciences
Feng-Feng CaiXiao-Yan Zhong
Current Medicinal Chemistry
Takayoshi Suzuki, Naoki Miyata
Current Opinion in Drug Discovery & Development
Roberto PapaitIan M Bonapace
© 2021 Meta ULC. All rights reserved